Abstract:The concentration of DKK1 was found to be increased by co‐culture with tumor organoids than when NFs were cultured alone. Furthermore, we measured serum DKK1 in patients with colorectal tumors to evaluated its usefulness as biomarker, The analysis revealed significantly higher serum DKK1 levels in the advanced cancer patient group than in the control group; th AUC was 0.78. Moreover, serum DKK1 concentration before and after treatment in patients with advanced adenoma showed a decrease in the after‐treatment group compared with that in the before‐treatment group; the AUC was 0.64. Background and Purpose Colorectal cancer progression from adenoma to cancer is a time‐intensive process; however, the interaction between normal fibroblasts (NFs) with early colorectal tumors, such as adenomas, remains unclear. Here, we analyzed the response of the microenvironment during early tumorigenesis using co‐cultures of organoids and NFs. Materials and Methods Colon normal epithelium, adenoma, cancer organoid, and NFs were established and co‐cultured using Transwell inserts. Microarray analysis of NFs was performed to identify factors expressed early in tumor growth. Immunostaining of clinical specimens was performed to localize the identified factor. Functional analysis was performed using HCT116 cells. Serum DKK1 levels were measured in patients with colorectal cancer and adenoma. Results Colorectal organoid–NF co‐culture resulted in increased organoid diameter and cell viability in normal epithelial and adenomatous organoids but not in cancer organoids. Microarray analysis of NFs revealed 18 genes with increased expression when co‐cultured with adenoma and cancer organoids. Immunohistochemical staining revealed DKK1 expression in the tumor stroma from early tumor growth. DKK1 stimulation reduced HCT116 cell proliferation, while DKK1 silencing by siRNA transfection increased cell proliferation. Serum DKK1 level was significantly higher in patients with advanced cancer and adenoma than in controls. Serum DKK1 level revealed area‐under‐the‐curve values of 0.78 and 0.64 for cancer and adenoma, respectively. Conclusion These findings contribute valuable insights into the early stages of colorectal tumorigenesis and suggest DKK1 as a tumor suppressor. Additionally, serum DKK1 levels could serve as a biomarker to identify both cancer and adenoma, offering diagnostic possibilities for early‐stage colon tumors. The present study has a few limitations. We considered using DKK1 as a candidate gene for gene transfer to organoids and NFs; however, it was difficult due to technical problems and the slow growth rate of NFs. Therefore, we used cancer cell lines instead. In addition, immunostaining and ELISA were based on the short‐term collection at a single institution, and further accumulation of such data is desirable. As described above, most previous reports were related to advanced cancers, but in this study, new findings were obtained by conducting experiments on endoscopically curable early‐stage tumors, such as adenomas.

Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

Effects of Altered Expression and Activity Levels of CK1δ and Ɛ on Tumor Growth and Survival of Colorectal Cancer Patients

Dickkopf 1 is expressed in normal fibroblasts during early stages of colorectal tumorigenesis

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

DKK4 Enhances Resistance to Chemotherapeutics 5-Fu and YN968D1 in Colorectal Cancer Cells.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Dickkopf-related protein 1 as a biomarker of local immune status and worse prognosis of Oral squamous cell carcinoma

DKK1 maintained cancer stem-like properties of esophageal carcinoma cells via ALDH1A1/SOX2 axis

Dickkopf-1 (DKK1) drives growth and metastases in castration-resistant prostate cancer

Identification of colon tumor marker NKD1 via integrated bioinformatics analysis and experimental validation

Dickkopf-1 is an immune infiltration-related prognostic biomarker of head and neck squamous cell carcinoma

Abstract 6246: WNT signaling-mediated DKC1 expression drives stemness associated with colorectal cancer

Dickkopf-1: A Promising Target for Cancer Immunotherapy

1382 DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers

High Expression of Dickkopf‐related Protein 1 is Related to Lymphatic Metastasis and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma Patients after Surgery

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01

Dkk1 as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Breast Cancer Patients

DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer

Elevated DKK1 Expression is an Independent Unfavorable Prognostic Indicator of Survival in Head and Neck Squamous Cell Carcinoma

The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types